Morgan Stanley initiated coverage of Belite Bio (BLTE) with an Overweight rating and $191 price target The firm says its key opinion leader checks support a multi-billion dollar opportunity for tinlarebant in Stargardt disease type 1. Potential regulatory approval and commercial launch are catalysts to move shares higher over the next 12 months, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLTE:
- Belite Bio: Tinlarebant’s First-Mover Advantage in STGD1 Supports Multi‑Billion Revenue Outlook and Further Upside Potential
- Belite Bio participates in a conference call with H.C. Wainwright
- Belite Bio Prices $350 Million ADS Offering to Boost Drug Development
- Belite Bio price target raised to $200 from $140 at Maxim
- Belite Bio 2.273M share Spot Secondary priced at $154.00